| abstract |
A method is provided for determining the sensitivity of an inhibitor treatment, particularly a combination treatment of an EGFR inhibitor with a chemotherapeutic agent. Phosphorylated AKT protein in the biological sample as an indicator that the biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor (EGFR) inhibitor and a chemotherapeutic agent. And / or measuring the overexpression of phosphorylated MAPK protein. An EGFR inhibitor is, for example, erlotinib (N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) quinazolin-4-amine). [Selection figure] None |